Matthew Jacobsen

Matthew Jacobsen

Auto-generated profile, based on publicly available information

Matthew Jacobsen

AstraZeneca, Cambridge, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
GBGabriel Balmus
Gabriel Balmus
DLDelphine Larrieu
Delphine Larrieu
ABAna C. Barros
Ana C. Barros
CCCasey Collins
Casey Collins
MAMonica Abrudan
Monica Abrudan
SJStephen P. Jackson
Stephen P. Jackson
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare, but devastating genetic disease characterized by segmental premature aging, with cardiovascular disease being the main cause of death. Cells from HGPS patients accumulate progerin, a permanently farnesylated, toxic form of Lamin A, disrupting the nuclear shape and chromatin organization, leading to DNA-damage accumulation and senescence. Therapeutic approaches targeting farnesylation or aiming to reduce progerin levels have provided only partial health improvements. Recently, we identified Remodelin, a small-molecule agent that leads to amelioration of HGPS cellular defects through inhibition of the enzyme N-acetyltransferase 10 (NAT10). Here, we show the preclinical data demonstrating that targeting NAT10 in vivo, either via chemical inhibition or genetic depletion, significantly enhances the healthspan in a Lmna G609G HGPS mouse model. Collectively, the data provided here highlights NAT10 as a potential therapeutic target for HGPS.

27 April 2024 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
XPXavier Palazzi
Xavier Palazzi
LALennart T. Anger
Lennart T. Anger
TBTheresa Boulineau
Theresa Boulineau
AGArmelle Grevot
Armelle Grevot
MGMagali Guffroy
Magali Guffroy
RWRichard Westhouse
Richard Westhouse

13 January 2019 in Toxicologic Pathology
Verified
Journal Article
Closed access
ABAlys Bradley
Alys Bradley
MJMatt Jacobsen
Matt Jacobsen
Whole slide imaging (WSI) technology has advanced to a point where it has replaced the glass slide as the primary means of pathology evaluation within many areas of medical pathology. The deployment of WSI in the field of toxicologic pathology has been delayed by a lack of clarity around the degree of validation required for its use on Good Laboratory Practice (GLP) studies. The current opinion piece attempts to provide a high-level overview of WSI technology to include basic methodology, advantages and disadvantages over a conventional microscope, validation status of WSI scanners, and perceived concerns over regulatory acceptance for the use of WSI for (GLP) peer review in the field of toxicologic pathology. Observations are based on the extensive use by AstraZeneca of WSI for the peer review of non-GLP studies conducted at Charles River facilities and represent the experiences of the authors. [Box: see text]

1 June 2021 in Toxicologic Pathology
Verified
Journal Article
Closed access
PDF file
MJMatt Jacobsen
Matt Jacobsen
ALArthur Lewis
Arthur Lewis
JBJames Baily
James Baily
AFAlain Fraser
Alain Fraser
DRDan Rudmann
Dan Rudmann
SRShane Ryan
Shane Ryan
The approach undertaken to deliver a Good Laboratory Practice (GLP) validation of whole slide images (WSIs) and the associated workflow for the digital primary evaluation and peer review of a GLP-compliant rodent inhalation toxicity study is described. The contract research organization (CRO) undertook validation of the slide scanner, scanner software, and associated database software. This provided a GLP validated environment within the database software for the primary histopathologic evaluation using WSI and viewed with the database software web viewer. The CRO also validated a cloud-based digital pathology platform that supported the upload and transfer of WSI and metadata to a cache within the sponsor's local area network. The sponsor undertook a separate GLP validation of the same cloud-based digital pathology platform to cover the download and review of the WSI. The establishment of a fit-for-purpose GLP-compliant workflow for WSI and successful deployment for the digital primary evaluation and peer review of a large GLP toxicology study enabled flexibility in accelerated global working and potential future reuse of digitized data for advanced artificial intelligence and machine learning image analysis.

1 August 2023 in Toxicologic Pathology
Verified
Journal Article
Closed access
AGArmelle Grevot
Armelle Grevot
JBJulie Boisclair
Julie Boisclair
MGMagali R. Guffroy
Magali R. Guffroy
PHPeter Hall
Peter Hall
GPGabriele Pohlmeyer-Esch
Gabriele Pohlmeyer-Esch
XPXavier Palazzi
Xavier Palazzi
In the last decade, numerous initiatives have emerged worldwide to reduce the use of animals in drug development, including more recently the introduction of Virtual Control Groups (VCGs) concept for nonclinical toxicity studies. Although replacement of concurrent controls (CCs) by virtual controls (VCs) represents an exciting opportunity, there are associated challenges that will be discussed in this paper with a more specific focus on anatomic pathology. Coordinated efforts will be needed from toxicologists, clinical and anatomic pathologists, and regulators to support approaches that will facilitate a staggered implementation of VCGs in nonclinical toxicity studies. Notably, the authors believe that a validated database for VC animals will need to include histopathology (digital) slides for microscopic assessment. Ultimately, the most important step lies in the validation of the concept by performing VCG and the full control group in parallel for studies of varying duration over a reasonable timespan to confirm there are no differences in outcomes (dual study design). The authors also discuss a hybrid approach, whereby control groups comprised both concurrent and VCs to demonstrate proof-of-concept. Once confidence is established by sponsors and regulators, VCs have the potential to replace some or all CC animals.

9 November 2015 in Veterinary Pathology
Verified
Journal Article
Open access
JBJ. Barnes
J. Barnes
PCP. Cotton
P. Cotton
SRS. Robinson
S. Robinson
MJM. Jacobsen
M. Jacobsen
AstraZeneca ran a bespoke study to generate age-matched clinical pathology and histopathology data from a cohort of Beagle dogs aged between 25 and 37 months to support the use of these older animals in routine preclinical toxicology studies. As the upper age range of Beagle dogs routinely used in toxicology studies does not normally exceed 24 months, there is an absence of appropriate age-matched historical control data. The generation of such data was crucial to understand whether age-related differences in spontaneous findings might confound the interpretation of toxicology study data. While the majority of the histopathology findings in all the older dogs occurred at a similar prevalence as those expected in young adult dogs (<24 months), a number of differences were observed in the thymus (involution), bone marrow (increased adiposity), testes (degenerative changes), and lung (fibrosis, pigment and alveolar hyperplasia) that could be misinterpreted as a test article effect. Minor differences in some clinical pathology values (hemoglobin, alkaline phosphatase, absolute reticulocytes) were of a small magnitude and considered unlikely to affect the interpretation of study data.